Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Evaluation of the safety and efficacy of Continuous Dopaminergic Stimulation by intracerebroventricular administration of anaerobically conserved dopamine in Parkinson's disease at the motor fluctuation stage: Single-center pilot study
Lacuna Pharma Pty Ltd
Parkinson's disease
1 trial -
Exaluren
Eloxx Pharmaceuticals
Alport Syndrome, X-Linked
1 trial -
Exenatide 3.5ΞΌg/mL solution for subcutaneous injection, Potassium canrenoate 5mg/mL solution for intravenous injection, Amodiaquine+Glibenclamide (10mg+0.1mg) /5mL oral suspension, Amodiaquine 2mg/mL solution for intravenous injection, Potassium canrenoate 25mg/5mL oral suspension
Lacuna Pharma Pty Ltd
Acute Ischemic Stroke
1 trial -
Exon 51 specific phosphorothioate oligonucleotide
BioMarin Pharmaceutical Australia Pty Ltd
Duchenne Muscular Dystrophy
1 trial -
Exon 51 specific phosphorothioate oligonucleotide
BioMarin Pharmaceutical Australia Pty Ltd
Duchenne Muscular Dystrophy
1 trial -
FEBUXOSTAT, ALLOPURINOL
Pari Pharma GmbH
Gout adult patients
1 trial -
FGF401
Novartis Pharmaceuticals
Hepatocellular Carcinoma (HCC)
1 trial -
FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, TOCILIZUMAB, YTB323
Novartis Pharmaceuticals
Systemic Lupus Erythematosus., Lupus Nephritis
1 trial -
FLUDARABINE PHOSPHATE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, BENDAMUSTINE, PHE885
Novartis Pharmaceuticals
Adult patients with relapsed and refractory multiple myeloma
1 trial -
FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE, TOCILIZUMAB
Novartis Pharmaceuticals
Difficult to treat rheumatoid arthritis, Severe, refractory Sjogrenβs disease with organ involvement
1 trial -
FLUOROURACIL , OXALIPLATIN , ABTL0812 Placebo, ABTL0812, IRINOTECAN , CALCIUM FOLINATE
Lacuna Pharma Pty Ltd
Metastatic pancreatic ductal adenocarcinoma
1 trial -
FORTRANS, poudre pour solution buvable en sachet., TOXICARB, suspension buvable
Pari Pharma GmbH
Major patients intoxicated by functional toxicant(s), hospitalized in intensive care and intubated.
1 trial -
FSD201
Quantum Biopharma
Mast Cell Activation Syndrome
1 trial -
FSD201
Quantum Biopharma
COVID-19
1 trial -
FWD1802
Forward Pharmaceuticals Co.,
Metastatic Breast Cancer
1 trial -
FWY003, FWY003, Placebo to FWY003, FWY003
Novartis Pharmaceuticals
Geographic atrophy secondary to age-related macular degeneration
1 trial -
Fancalen
Lacuna Pharma Pty Ltd
Fanconi anemia (subtype A)
1 trial -
Fazisiran Injection
Arrowhead Pharmaceuticals Ireland Limited
Alpha 1-Antitrypsin Deficiency
1 trial -
Fentanyl
Teva Pharma GmbH
Cancer
1 trial -
Fentanyl Buccal Tablet
Teva Pharma GmbH
Advanced Cancers
1 trial -
Film-coated tablet, Major Ingredients Mannitol, microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, macrogol, titanium dioxide and talc, Fipaxalparant
Elan Pharma International
Diffuse Cutaneous Systemic Sclerosis
1 trial -
Fipaxalparant
Elan Pharma International
Diffuse Cutaneous Systemic Sclerosis
1 trial -
Fipaxalparant, Film-coated tablet, Major Ingredients Mannitol, microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, macrogol, titanium dioxide and talc
Elan Pharma International
Idiopathic Pulmonary Fibrosis
1 trial -
First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression (TEMOTRAD01)
Pari Pharma GmbH
Adults with non-contrast-enhancing diffuse brainstem gliomas with non-threatening infiltrative clinical and/or radiological progression, Adult brain stem gliomas
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources